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Abstract
Aims Patients with chronic heart failure (CHF) struggle to follow self‐care plans, which may lead to worsening illness and
poor quality of life. Burden of treatment (BoT) describes this workload and its impact on patients’ lives. Suggesting the balance
between a patient’s treatment workload and their capability to manage it is crucial. If BoT is reduced, self‐care engagement
and quality of life may improve. This article describes the SYMPACT study design and methods used to explore how symptoms
and management tasks impact CHF patients’ lives.
Methods and results We used a sequential exploratory mixed‐methods design to investigate the interaction between
symptoms and BoT in CHF patients.
Conclusions If symptoms and BoT are intrinsically linked, then the high level of symptoms experienced by CHF patients may
lead to increased treatment burden, which likely decreases patients’ engagement with self‐care plans. SYMPACT may identify
modifiable factors to improve CHF patients’ experience.
Keywords Chronic heart failure; Burden of treatment; Symptom burden; Self‐care; Mixed methods; Study design
Received: 22 February 2020; Revised: 16 May 2020; Accepted: 27 August 2020
*Correspondence to: Rosalynn C. Austin, Queen Alexandra Hospital, C-Level, Southwick Hill, Cosham, Portsmouth PO6 3LY, UK. Email: r.c.austin@soton.ac.uk
Introduction
Patients with chronic heart failure (CHF) often struggle to
adhere to self‐care expectations.1 Non‐compliance with
self‐care is suggested as a contributor to poor outcomes in
CHF and is attributed to self‐care that is neither sufficient
nor effective.2 Burden of treatment (BoT) is composed of
dynamic states of workload (time and energy required to
treat and manage a condition) and individual capacity (factors
that alter ability to do work).3–7 Overwhelming treatment
burden may be associated with adverse clinical outcomes.4,6
Patient responsibility and engagement with self‐care adding
to BoT are not unique to CHF.7 Clinical pathways and personal
capacity appear to influence BoT in lung cancer and COPD.8
BoT appears to be exacerbated by the level of support
provided by health care systems and socio‐economic
disadvantages in end‐stage kidney disease.9 How symptoms
interact with burden of treatment has yet to be investigated.
CHF is a life‐limiting syndrome, and patients experience
persistent, progressive, and debilitating symptoms such as
breathlessness, fatigue, and oedema, compromising their
quality of life (QoL) despite optimized clinical treatment
plans.10 Complete elimination of symptoms is unlikely, yet
there are likely treatment options that could help
reduce symptoms. Lower symptom burden is associated
with improved functional ability and better self‐care
engagement.11 While the theory of BoT acknowledges
symptom burden, it argues that symptoms are theoretically
distinct. Examination of the literature, clinical observations,
and patient and public involvement (PPI) suggests that the
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symptoms in CHF may directly interact with BoT.12 In this
study, possible interactions between BoT and symptom
burden will be measured quantitatively and explored
qualitatively through interviews, facilitating a deeper
understanding of how patients with CHF experience burden
of treatment. This paper outlines the design of the study:
‘How do SYMptoms and management tasks in chronic heart
failure imPACT a patient’s life (SYMPACT)?’ SYMPACT will ex-
amine and explore the interaction of symptoms experienced
by patients with CHF with BoT. The authors will test and
explore the hypothesis (aims) that symptoms are intrinsically
linked with BoT; that is, patients with lower reported
symptoms will report lower BoT, and patients with higher
reported symptoms will report higher BoT. This will be
confirmed in how patients describe their experience. The
research questions are as follows: (Phase I) Is there a
relationship between quantitatively measured symptoms
and BoT? (Phase II) What is the perspective of patients with
FIGURE 1 SYMPACT study design overview: flowchart illustrating the phases of SYMPACT and how they inform each other.
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CHF on their experienced symptom burden and BoT? (Phase
III) How do symptoms interact with BoT in CHF?
Study design
SYMPACT is a sequential explanatory mixed‐methods study
(Figure 1); this methodology promotes the exploration of re-
sults in a quantitative study.13,14 Qualitative results expand
on insights derived from quantitative results,14 facilitating
deeper explanations of observed statistical relationships.
Combining the SYMPACT study results with a qualitative liter-
ature synthesis15 enables the adductive analysis approach16
to form a conceptual model of the interaction between BoT
and symptom burden in CHF.
SYMPACT adheres to the Declaration of Helsinki and has
been reviewed and approved by the University of Southamp-
ton Ethics Committee (ERGO: 41287) and the Nottingham
HRA1 Research Ethic Committee, Health Research Authority
(MREC: 18/EM/0339, IRAS: 247773).
Phase I: multi‐centre survey of symptoms and
burden of treatment in chronic heart failure
Phase I of SYMPACT will test the following hypothesis: symp-
tom burden reported by CHF patients will be correlated with
reported domains of BoT.
Design
A single time point survey using three validated question-
naires is used.
Participants
This is a multi‐centre study across primary and secondary
care National Health Service (NHS) health trusts in the UK.
English‐speaking adults with CHF (minimum of 6 months),
and in the investigators’ opinion are not cognitively impaired,
will be invited to complete the questionnaires. Patients with
heart transplant or who are receiving palliative care will
be excluded.
Methods
Following informed consent, health information will be col-
lected: (i) demographics (age, gender, ethnicity, marital sta-
tus, and living situation), (ii) CHF characteristics [diagnosis
date, aetiology, New York Heart Association (NYHA) class,
ejection fraction, and clinical evaluations], and (iii) personal
health information (health issues, medications, and
hospitalizations).
Patients will be invited to complete three validated
questionnaires: Heart Failure Symptom Survey (HFSS),17 Min-
nesota Living with Heart Failure Questionnaire (MLHFQ),18
and the Patient Experience with Treatment and Self‐Care
(PETS).19
a HFSS is a reliable disease‐specific evaluation of heart
failure signs and symptoms.17 It measures the frequency,
severity, and impact of 14 symptoms, where the higher
score equates to more severe experience.
b MLHFQ captures key physical, emotional, social, and men-
tal dimensions of QoL in a brief questionnaire.20 Lower
scores on the MLHFQ relate to better health related QoL.
c PETS describes the work of illness, facilitating tools, and
exacerbating factors involved in self‐care of generic
chronic illness. It is a 48‐item questionnaire quantifying
the patient experience of BoT across nine domains.19
Sample size
Sample size calculation is based on estimating the correlation
between the above measures, to within a pre‐specified preci-
sion (as defined by the 95% confidence interval). A width of
0.2 was chosen as a balance between the practical consider-
ations and the ability to draw useful conclusions on the ob-
served correlations. Pearson’s correlation power calculation
formula21 suggests that a sample of size 350 will achieve this
for any value of correlation.
Data analysis
Descriptive statistics will be used to summarize the study par-
ticipants’ personal, CHF, and health characteristics. Patients’
questionnaire responses will be described across gender,
age, number of health issues and medications, and NYHA
class and according to left ventricular ejection fraction.
A scatter plot will be used to visually assess the relation-
ship between reported symptom burden (measured by
HFSS and MLHFQ) and BoT (measured by PETS); this will
guide the choice of a suitable correlation tool (e.g.
Pearson’s or Spearman’s) to summarize the relationship
between the variables. Correlations will be presented with
95% confidence intervals.
An interim analysis will occur at about the halfway point.
These results will be used to adapt the interview schedule,
with specific probes to be used in Phase II.
Limitations
Limiting the sample to only three hospitals in a single county
in the UK and patients who only speak English may reduce
the generalizability of the results. Further, limiting the sample
to CHF patients without heart transplants will ensure a focus
to the generic lived experience of CHF. These limitations were
thought to be reasonable owing to limited availability of
translated versions of the validated questionnaires and the
aim of the project.
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Phase II: semi‐structured interviews
CHF patients who complete Phase I will be invited to take
part in a semi‐structured interview. The aim of this phase is
to explore their experiences of living with CHF and elaborate
on their questionnaire responses.
Design
Semi‐structured interviews will be conducted at either a
health care facility or the participant’s home, according to
patient choice. Using the interim results of the questionnaires
as probes in the interview should encourage in‐depth
description of experience of BoT, thereby substantiating
the results from Phase I or providing explanation for
differences observed.
Participants
Phase I patients are eligible to participate in Phase II. Phase II
will begin after the completion of the interim analysis.
Sampling
Sample size will be defined by data saturation when three
consecutive interviews do not generate any new
information.22 A maximum variation sampling technique will
be used, ensuring that the Phase II sample is representative
of the Phase I sample population.
Methods
Interviews will be audio recorded, and the interviewer may
take field notes.
SYMPACT Phase II interview schedule is based on previous
interview questions developed by other researchers inter-
ested in BoT5,23–26 and cover domains measured by PETS
(Data S1: Interview schedule for Phase II). Further probing
questions developed from Phase I interim results will be
added to the interview schedule. Following the interview, re-
searcher reflections on the interview will be audio recorded
to promote transparency and reflexivity.
Data analysis
All interviews and researcher reflections will be transcribed.
Field notes, where appropriate, are converted into Word doc-
uments. All participant identifiers in the interview data will be
coded using their participant unique study number, assigned
in Phase I.
Analysis of the interviews will follow an adapted form of
Thomas and Harden’s methods for thematic synthesis.27 With
the use of NVIVO (QRS Internationals), the interview tran-
scripts and researcher notes will be examined line by line
for symptom terminology. These will form the initial nodes.
Coding credibility will be achieved through member checking
(PPI, clinical expert, and co‐authors).28 Each symptom node
will be read in its context and a descriptive theme created.
Finally, descriptive themes will be examined for similarities
to the ‘a priori’ BoT framework. Constant comparison,
reflexivity, and discussion with co‐researchers will increase
rigour and trustworthiness.29
The a priori BoT framework incorporates the following: (1)
workload: involving the effort required to enact tasks (techni-
cal and logistic), alter relationships (activate support and seek
assistance), and evaluate outcomes of treatments (under-
standing and evaluation).5,23 (2) Individual capacity:
Encompassing an individual’s abilities, their resources, and
their readiness to address the workload. Including consider-
ation of a patient’s physical function, cognitive function, emo-
tional status, socio‐economic resources, social support
networks, literacy, culture, and beliefs.6 (3) Impact: Alter-
ations to the patient’s perception of self and their role. In-
cluding factors that make adhering to treatment plans
more difficult.5,7
Phase III: data integration
Data integration for SYMPACT was planned in the study de-
sign. The validated questionnaires used were chosen accord-
ing to theoretical similarities to BoT theory (detailed in Table
1). The data from Phase I and Phase II will be integrated to
inform the understanding of how symptoms interact with
BoT in CHF. Symptom nodes and descriptive themes (Phase
II) will be transformed through content analysis30 and com-
pared with the symptom burden scores (HFSS and MLHFQ)
and BoT scores (PETS) from Phase I, providing greater depth
and insight to the patient experience. Through constantly
comparing codes to the data,13 the descriptive themes will
be refined and explored for points of interaction with the a
priori BoT framework. This process should provide qualitative
narratives to build on the statistical results from Phase I.
Patient and public involvement
The PPI group (members of the Patient Research Ambassa-
dors’ from the Portsmouth Hospitals University NHS Trustl)
comprised members of the public with a variety of chronic
conditions, including carers of people with CHF. They stated
that SYMPACT asks a valuable question that they identified
as being important to their experience as patients and carers.
They approved of the study design, as it would encourage
participants to provide more in‐depth information not cov-
ered by the questionnaires in this emerging field, which was
of great importance to them, as they felt that often patient
questionnaires do not ask the questions that are important
to them. They provided guidance around study design ele-
ments that helped to decrease the study burden for partici-
pants. They assisted in the production of the participant
and public‐facing documents as well as refining and
rephrasing interview questions for Phase II. They agreed to
help promote SYMPACT, perform credibility checks (part of
data analysis plan for Phase II), and assist in result dissemina-
tion. This group is and continues to be an integral part to this
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project, and the primary author holds regular meetings with
them keeping them apprised of progress and to encourage
their input.
Discussion
Patients with CHF have high symptom burden and are ex-
pected to self‐manage an illness with poor QoL and high rates
of morbidity and mortality. Despite marked progress with
medical and device treatments, readmission rates due to per-
ceived non‐adherence remain high and QoL are poor. CHF
prevalence is expected to rise, and the current demands on
health care systems are already high. BoT provides a different
perspective for examining the patient experience. It is
thought that overwhelming treatment burden can lead to
poor engagement with self‐care, which may contribute to
poor outcomes. SYMPACT proposes a detailed measurement
and exploration of treatment burden in patients with CHF. By
exploring if symptoms interact with BoT, modifiable factors
may be highlighted, providing the starting point for a
patient‐focused intervention. Further, as there are similarities
in self‐care expectations between CHF and other chronic ill-
nesses, this study may also offer transferable knowledge to
the understanding of BoT across multiple chronic illnesses.
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Table 1 Data integration overview for SYMPACT
A priori BoT framework
Phase I (Quantitative) variable
measured Phase II (Qualitative) question theme
Workload
Enact tasks Clinical demanda
PETS domainsb
What tasks are performed in managing chronic heart failure? Does anyone
help with this?Alter relationships
Evaluate outcomes
Individual capacity
Individual’s ability Clinical characteristicsc
Personal characteristicsd
HFSS total score
What makes managing chronic heart failure more difficult or easy?
Resources and readiness
Impact
Alterations to self and
role
MLHFQ total score
HFSS interference scorese
PETS domainsb
How does the work of managing chronic heart failure impact their life?
Factors influencing
adherence
aClinical demands: number of health issues, number of medications, hospitalizations within a year.
bPETS domains: sub‐scores in PETS by work (e.g. medication management and attending appointment), facilitating tools, and exacerbat-
ing factors involved in self‐care.
cClinical characteristics: NYHA classification, aetiology, ejection fraction, CHF type, and years since diagnosis.
dPersonal characteristics: age, gender, marital status, and living situation.
eHFSS interference scores: sub‐scale in HFSS that captures reported interference with physical activity and enjoyment of life.
How do SYMPtoms and management tasks in chronic heart failure imPACT a person’s life (SYMPACT)? Protocol for a mixed‐methods study5
ESC Heart Failure (2020)
DOI: 10.1002/ehf2.13010
Supporting information
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
Data S1. Interview schedule for Phase II
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